PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Penumbra (PEN) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) sees strong growth across all geographical regions and product lines in Q4.
Integra LifeSciences (IART) Beats on Q4 Earnings & Revenues
by Zacks Equity Research
Integra LifeSciences's (IART) solid Q4 revenue growth was primarily driven by high organic revenues and better-than-expected performance by the recently-acquired businesses.
Medtronic (MDT) Expands in the U.S. with 2.0mm DES Launch
by Zacks Equity Research
Medtronic (MDT) consistently focuses on boosting CSH segment.
NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View
by Zacks Equity Research
NuVasive (NUVA) gains on continued growth in international business in Q4.
PetMed (PET) Focuses on Advertising to Boost New Order Sales
by Zacks Equity Research
PetMed (PETS) implements several strategies to revitalize top line.
STERIS Focuses on Expanding Core Business, Competition Rife
by Zacks Equity Research
STERIS (STE) pursues six acquisitions in the first nine months of fiscal 2018.
PerkinElmer (PKI) Down 6.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health Strong on Medical & Pharmaceutical Segments
by Zacks Equity Research
Cardinal Health (CAH) gains large number of Pharmaceutical Distribution customers.
Here's Why You Should Invest in LabCorp (LH) Stock Right Now
by Zacks Equity Research
Strong guidance and Covance Drug Development's sturdy growth raise investors optimism on LabCorp (LH).
Medtronic (MDT) Unveils MiniMed Mio Advance Infusion Set
by Zacks Equity Research
Medtronic (MDT) continues to adopt initiatives to drive the performance of its Diabetes segment.
Integer Holdings (ITGR) Beats on Q4 Earnings, Issues '18 View
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter 2017 results benefit from strong performance in its Medical and Non-Medical units.
5 Reasons Why You Should Add Becton, Dickinson (BDX) Now
by Zacks Equity Research
Becton, Dickinson's (BDX) strategic acquisition of C.R. Bard provides it a strong foothold and exposure in MedTech. Here we take a look at five other factors that are likely to boost the stock.
Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Recent buyouts and CE Mark boost investors' confidence in Edwards Lifesciences (EW).
Ecolab (ECL) Misses Q4 Earnings Estimates, View Impressive
by Zacks Equity Research
Despite strength in Global Industrial and Global Institutional segments, Ecolab (ECL) ended the fourth quarter on an unfavorable note.
Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat
by Zacks Equity Research
Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor confidence on strong companion animal business along with growth across all segments.
Medtronic (MDT) Beats on Q3 Earnings, Reiterates FY18 View
by Zacks Equity Research
Medtronic (MDT) rides high on strength in all business segments in Q3.
Myriad Genetics Banks on Product Launches, Competition Rife
by Zacks Equity Research
Myriad Genetics (MYGN) focuses on strengthening the Molecular Diagnostics portfolio through product launches.
Abiomed Hits New 52-Week High: 4 Factors Driving the Stock
by Zacks Equity Research
Abiomed's (ABMD) recent regulatory approvals and raised guidance boost investors' confidence.
Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm
by Zacks Equity Research
Edward Lifesciences (EW) witnesses multiple developments in THV segment.
Medtronic's Positive Study Results May Expand Customer Base
by Zacks Equity Research
Medtronic (MDT) leaves no stone unturned to boost the performance of its Diabetes business.
Cardiovascular Systems Portfolio Solid, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) expands product portfolio to enhance market reach.
Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.
Chemed (CHE) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q4.